In summary, the CR rates in DLBCL and FL patients treated with the CD47 antibody, Hu5F9-G4, and rituximab were 33% and 43%, respectively, while the ORR in patients with DLBCL who were treated with TTI-621 (SIPRαFc) and rituximab, was 21%. Here, CD47 is linked to diffuse large B-cell lymphoma.